Werewolf Therapeutics warns of going concern doubt as survival hinges on its pending merger with Ambros Therapeutics.
SEC EDGAR, 2026-11-13: 10-Q — "substantial doubt", "material weakness"
Werewolf Therapeutics warns of going concern doubt as survival hinges on its pending merger with Ambros Therapeutics.
Company: Werewolf Therapeutics, Inc. (HOWL) Filed: November 13, 2026, 10-Q Phrase: "substantial doubt" — "We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date that these condensed consolidated financial statements are issued in this Quarterly Report." What the filing says: Werewolf Therapeutics reported having cash and cash equivalents of $41.9 million as of September 30, 2026, and an accumulated deficit of $495.1 million. The company stated that its current cash resources are insufficient to fund its operating plan for the next twelve months, raising substantial doubt about its ability to continue as a going concern. Its ability to maintain ongoing operations is highly dependent on successfully consummating its pending merger with Ambros Therapeutics, Inc. (originally agreed on August 21, 2026) and the concurrent $150.0 million PIPE financing. If the merger is not completed, the company will need to find alternative funding, significantly reduce or discontinue operations, or pursue a dissolution and liquidation. Two ways it goes: A. The merger with Ambros and the concurrent $150.0 million PIPE financing are successfully completed. B. The merger fails to close, forcing the company to seek alternative strategic transactions, curtail operations, or dissolve. Next date: December 17, 2026, the scheduled special meeting of Werewolf stockholders to vote on the merger. Watch: Stockholder vote results and the closing of the merger. Tags: going concern, being acquired, event changed fundamentals